Inovio's Zika vaccine will be the 14th drug the company has in testing, but its CEO insisted Tuesday the company is not spread too thin.
Jim Cramer breaks down the next hurdles the market has to jump over.
Jim Cramer lays out his game plan for Brexit action next week, and has his eye on black gold to hold the key on when to move.
Cash hoards sitting inside the world's biggest technology companies come with a big asterisk. Breakingviews explains the reasons.
Bespoke Investment Group examines the relationship between high-quality versus low-quality stocks in order to find investment opportunities.
Discussing the current state of valuation in the markets with Chad Morganlander, Stifel Portfolio Manager, and Jack Ablin, BMO Private Bank Executive VP & Chief Investment Officer.
Bob Bechek from management consulting firm Bain & Company, has been named the U.S.’ highest rated CEO of 2016, according to Glassdoor.
New data from eVestment shows that Facebook stock is now ranked 14th among institutional holders.
U.S. stocks closed at session highs Thursday, with health care stocks leading, ahead of the highly anticipated employment report due Friday morning.
Some of the names on the move ahead of the open.
Johnson & Johnson said it would acquire Vogue International for $3.3 billion, adding brands such as OGX shampoos and FX hair styling products.
Stocks to put away for a rainy day with the Fast Money traders.
CNBC's Meg Tirrell reports on Johnson & Johnson after it lost a second lawsuit linking its baby powder to cancer, and speaks with CEO Alex Gorsky at the company's analyst day.
J&J's consumer brands and medical devices units are poised for growth following turnaround efforts, CEO Alex Gorsky says.
Johnson & Johnson CEO Alex Gorsky talks about implementing the company's turnaround plan and addesses safety concerns about talcum powder.
CNBC's Meg Tirrell talks with Johnson & Johnson CEO Alex Gorsky about his plans to grow consumer brands and medical devices.
CNBC's Meg Tirrell reports Johnson & Johnson expects to see $6 billion in sales potential from its new devices and projects five $1 billion consumer brands by 2020, including Listerine, Neutrogena and Johnson's Baby.
Jim Cramer broke down the stocks of the Dow one by one and offered his insight on where to take action.
Jim Cramer marked the anniversary of the market hitting an all-time high one year ago with an in-depth analysis of the Dow Jones.
Shares of Johnson & Johnson dipped briefly Friday after an analyst took aim at the company's medical device business.